Načítá se...
Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report
We describe the case of a 44-year-old female patient on rituximab for the treatment of multiple sclerosis with undetectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG specific antibodies 18 days after the second dose of SARS-CoV-2 vaccine. Interferon-gamma release assay testing...
Uloženo v:
| Vydáno v: | Int J Infect Dis |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243639/ https://ncbi.nlm.nih.gov/pubmed/34216738 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2021.06.054 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|